Supplementary Table 1 from A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors

de Bono JS., Williams A., Melero I., Jayaram A., Hawley JE., Doger de Speville B., Moreno I., Castellano D., Reig Ò., Knapen DG., Anguera G., Martinez J., Gort E., de Jonge M., Alonso-Romero JL., Boni V., Perez-Gracia JL., Falcon A., de Groot DJ., Pierce AJ., Leishman AJ., Lloyd P., Bartlett PD., Bland-Ward P., Chau A., Song M., Duffy K., Hashimoto K., de Vries E.